Items Per Page 102550 Year All20242023202220212020201920182017 April 24, 2024 ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference PDF Version April 22, 2024 ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients PDF Version April 20, 2024 ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice April 12, 2024 ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update PDF Version March 27, 2024 Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders PDF Version March 12, 2024 ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering PDF Version March 11, 2024 ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients PDF Version March 6, 2024 ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors PDF Version February 29, 2024 ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat PDF Version January 2, 2024 ASLAN Pharmaceuticals Announces Participation in January Investor Conferences PDF Version
April 24, 2024 ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference PDF Version
April 22, 2024 ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients PDF Version
April 12, 2024 ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update PDF Version
March 27, 2024 Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders PDF Version
March 11, 2024 ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients PDF Version
March 6, 2024 ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors PDF Version
February 29, 2024 ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat PDF Version
January 2, 2024 ASLAN Pharmaceuticals Announces Participation in January Investor Conferences PDF Version